Trial · NCT02261805
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 44
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Ganetespib and Doxorubicin | 3 | 11 | 3 |
| other | Dysgeusia | Nervous system disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Fatigue | General disorders | Ganetespib and Doxorubicin | 6 | 11 | 7 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
| other | Alkaline phosphatase increased | Blood and lymphatic system disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
| other | Anemia | Blood and lymphatic system disorders | Ganetespib and Doxorubicin | 3 | 11 | 4 |
| other | Depression | Psychiatric disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Ganetespib and Doxorubicin | 5 | 11 | 10 |
| other | Dyspepsia | Gastrointestinal disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
| other | Headache | Nervous system disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Nausea | General disorders | Ganetespib and Doxorubicin | 8 | 11 | 8 |
| other | Neutrophil count decreased | Immune system disorders | Ganetespib and Doxorubicin | 4 | 11 | 4 |
| other | Pain | Nervous system disorders | Ganetespib and Doxorubicin | 2 | 11 | 2 |
| other | Anorexia | General disorders | Ganetespib and Doxorubicin | 3 | 11 | 4 |
| other | Aspartate aminotransferase increased | Hepatobiliary disorders | Ganetespib and Doxorubicin | 2 | 11 | 3 |
| other | Hyponatremia | Blood and lymphatic system disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Insomnia | General disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
| other | Lymphocyte count decreased | Immune system disorders | Ganetespib and Doxorubicin | 1 | 11 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Ganetespib and Doxorubicin | 1 | 11 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02261805/events